After helping to develop and test new mRNA technologies for COVID-19 vaccines, University of Maryland School of Medicine (UMSOM) researchers and scientists...
Lyme disease is the most common vector-borne illness in the United States.2 And yet, the actual cases are vastly underreported. The U.S. Centers for Diseas...
Pfizer Inc. (NYSE:PFE) announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Supplemental New Drug Applications (sNDAs) fo...
Preclinical data demonstrate the efficacy of TNX‐801 vaccination against mpox virus challenge in a non-human primate model Phase 1 trial with TN...
One promising approach involves delivering antiviral compounds vaginally, using inserts, gels, films, or intravaginal rings. This method is appealing becau...
Xylyx Bio, a regenerative medicine company developing breakthrough technologies for organ and tissue repair, today announced findings from an independent c...
Jingsong Wang, MD, PhD, Chairman of Nona Biosciences, said, " By combining our respective expertise in antibody engineering and the disease area, we a...
Epinephrine Injection, USP, is indicated for emergency treatment of allergic reactions (Type I), including anaphylaxis, which may result from insect stings...
Coloplast has finalised its first pivotal clinical study on Luja, a new intermittent male catheter, designed to reduce the risk of urinary tract infections...
Data shows reduction of microglia activation and improvement in behavior in rodent model of Alzheimer’s disease (AD) Modulation of neuroinflammati...
Today, NEC and NOI announced that NOI will be realigned as a subsidiary of NEC Bio B.V. (NB) in Hilversum, Netherlands, a newly established wholly owned su...
Søren Tulstrup, President and CEO, Hansa Biopharma said, "This phase 2 study of imlifidase in GBS is an important next step in understanding the rol...
Dermatology industry veteran Thibaud Portal, PhD appointed as CEO Granular Therapeutics, (Granular) a private biotech company specialising in p...
Patients with inflammatory diseases being treated with therapeutic monoclonal antibodies (mAbs) such as Infliximab may experience a significant increase in...
© 2025 Biopharma Boardroom. All Rights Reserved.
